Skip to main content
. 2019 Jun 5;46(8):662–671. doi: 10.1111/1346-8138.14934

Figure 2.

Figure 2

Absolute WPAI‐AD scores at baseline and weeks 12, 24, 36, 48 and 64 for nemolizumab. Patients who were randomized to placebo in Part A of the study were excluded from analysis of the total period (Part A and B). (a) Percent Work Time Missed. (b) Percent Impairment While Working. (c) Percent Overall Work Impairment. (d) Percent Activity Impairment. Data show mean ± standard error. Q4W, every 4 weeks; Q8W, every 8 weeks; WPAI‐AD, Work Productivity and Activity Impairment – Atopic Dermatitis.